Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers
I'm LongbridgeAI, I can summarize articles.Silexion Therapeutics released a corporate deck highlighting SIL204, a second-generation siRNA targeting KRAS-driven solid tumors. The Phase 2/3 program for locally advanced pancreatic cancer employs dual delivery: intratumoral for primary tumors and subcutaneous for micrometastases. Key endpoints include overall survival and ctDNA biomarkers expected by Q4 2026. The trial schedule includes a safety run-in completing Q2 2027, Phase 2 expansion in Q3 2027, and Phase 3 confirmation starting Q3 2030.
- Silexion highlighted SIL204, a second-generation siRNA designed to silence KRAS expression in KRAS-driven solid tumors, including PDAC, CRC, NSCLC. * Phase 2⁄3 program launched for locally advanced pancreatic cancer using dual delivery: intratumoral dosing for primary tumors, subcutaneous dosing for micrometastases. * Primary endpoint is overall survival; secondary endpoints include ctDNA biomarkers expected early Q4 2026, progression-free survival, overall response rate. * Trial plan calls for a safety run-in completing Q2 2027, a Phase 2 expansion starting Q3 2027, a Phase 3 confirmatory stage starting Q3 2030. * Company cited a total addressable market of USD 2 billion in the U.S., USD 3 billion in the EU for localized advanced pancreatic cancer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief on August 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here